Hyperway Pharma Secures Over 200 Million CNY in Series B Funding

Chengdu Hyperway Pharmaceutical Co., Ltd. (“Hyperway Pharma”) recently announced the successful completion of its Series B financing round, raising over 200 million CNY. The round was led by Huagai Capital, with participation from SIP Sungent BioVenture Venture Capital, Tao Capital, Panlin Capital, and other prominent institutions. Existing shareholder Xincheng Fund also increased its investment, reaffirming long-term confidence in the company. Haoyue Capital acted as the exclusive financial advisor.

Proceeds from this round will primarily support clinical development of Hyperway Pharma’s leading innovative drug candidates—HBW-004285, HBW-012336, HBW-012462, HBW-3220, and HBW-3210—and advance multiple preclinical programs. This funding marks a significant milestone in accelerating the company’s transition from research to clinical trials, commercialization, and global expansion.

The participation of top-tier biopharmaceutical investors underscores strong market confidence in Hyperway Pharma’s innovation strategy and pipeline potential. This capital infusion provides powerful momentum for the global translation of its drug candidates and reinforces the company’s commitment to its mission: “Develop Quality Medicines, Innovate in China.”

Dr. Yingfu Li, Chairman of Hyperway Pharma, commented: “We are deeply honored by the recognition and support from leading professional investment institutions. Our sincere thanks go to both new and existing shareholders for their trust, and to Haoyue Capital for their professional guidance throughout this process. After six years of rapid growth, Hyperway Pharma has entered a pivotal phase. The oversubscription of this round is a strong endorsement of our progress and future potential. We remain firmly committed to developing original, globally competitive therapies and will continue to accelerate clinical research, drive commercialization, and deliver sustained value to our stakeholders. Through innovation and dedication, we aim to fulfill our corporate philosophy of ‘providing quality medicine to benefit the people’, bringing transformative treatments to patients worldwide.”

Statement from Huagai Capital’s Healthcare Investment Team: “We are highly impressed by Hyperway Pharma’s rapid progress in the field of innovative drug development. Under the leadership of Dr. Yingfu Li, the company has demonstrated outstanding R&D efficiency, building a robust and differentiated pipeline across multiple therapeutic areas, including oncology and pain management. We particularly value the strategic foresight reflected in its pipeline design—whether it’s a next-generation BTK inhibitor tackling resistance mechanisms, a non-opioid analgesic with strong safety potential, or a novel molecule targeting the historically ‘undruggable’ KRAS pathway. Each program holds significant promise to become a global best-in-class therapy. Huagai Capital is proud to support Hyperway Pharma and will continue to provide full backing as the company advances these high-impact therapies toward commercialization, ultimately benefiting patients around the world.

Mr. Kechun Li, Partner at SIP Sungent BioVenture Ventures, remarked: “We are honored to invest in Hyperway Pharma. Dr. Yingfu Li, the company’s founder, is a globally recognized medicinal chemist with over 30 years of R&D and leadership experience across Germany, Japan, multinational pharmaceutical companies in the U.S., and China. He has served as the lead discoverer and principal investigator for multiple Class I innovative drugs. Notably, during his tenure at Bayer, Dr. Li led the development of BAY61-3606—the world’s first Syk inhibitor—which is now widely used in clinical practice. In addition to his achievements in novel drug discovery, Dr. Li has overseen the development of numerous complex generics at Chinese pharmaceutical firms. Under his leadership, Hyperway Pharma has developed a fourth-generation BTK inhibitor with superior pharmacologic and toxicologic profiles compared to currently marketed BTK therapies. The company’s NaV1.8-targeting non-opioid analgesic also shows enhanced safety and clinical potential relative to Vertex’s Journavx, which was named TIME Magazine’s Invention of the Year. Since its founding six years ago, Hyperway Pharma has remained committed to rapid, efficient, and high-quality innovation. The company has secured 11 PCCs and 7 clinical trial approvals, with each pipeline demonstrating meaningful differentiation in head-to-head comparisons with clinical benchmarks. We are confident that, under Dr. Li’s visionary leadership and the team’s continued dedication, Hyperway Pharma will accelerate the commercialization of its pipeline and continue to deliver transformative therapies.”

Statement from Tao Capital: “Hyperway Pharma remains at the forefront of global small molecule drug innovation, with a pipeline focused on high-value, technically challenging targets such as Nav1.8, BTK, KRAS-G12D, and pan-KRAS. We are particularly optimistic about the commercial and clinical potential of its fourth-generation BTK inhibitor in hematologic malignancies and oral autoimmune indications. In addition, Hyperway Pharma’s Nav1.8-targeting analgesic exhibits a broad therapeutic window and superior pharmacokinetic properties compared to the only approved competitor, Vertex-548. Its efficacy and development trajectory have already positioned it among global leaders in the field. With Dr. Yingfu Li’s unwavering commitment to innovation and the team’s deep expertise, we believe Hyperway Pharma is well poised to deliver multiple best-in-class therapies that will make a meaningful impact on patients worldwide.”

Statement from Panlin Capital’s Biopharma Investment Team: “Pain and oncology remain areas of significant unmet clinical need. Hyperway Pharma, with its deep expertise in small-molecule innovation and strong disease insight, has built a portfolio of differentiated pipelines that continue to achieve meaningful clinical milestones. We are confident in the team’s sustained capacity for technological innovation and exceptional execution. Looking ahead, we believe Hyperway Pharma is well positioned to advance globally competitive therapies and deliver breakthrough treatment options that address critical patient needs.”

Dr. Xiaoxiao Peng, Managing Director of Xincheng Fund, commented: “Hyperway Pharma’s forward-looking pipeline strategy in pain and oncology reflects its strong innovation capabilities and differentiated scientific approach. The company’s Nav1.8 inhibitor is advancing ahead of schedule, supported by promising early clinical data, and the team is now fully engaged in Phase II enrollment. We believe this funding round will significantly accelerate the development of Hyperway Pharma’s core programs, helping to bring transformative therapies to market and improve outcomes for patients worldwide.”

Dr. Zisheng Kang, Managing Director of Haoyue Capital, commented: “It has been a privilege to support such an exceptional team. Dr. Yingfu Li brings a global perspective to drug innovation, having strategically positioned multiple high-potential pipelines years in advance. The Hyperway Pharma team consistently demonstrates remarkable efficiency and cohesion. Despite operating with modest funding since inception, the company has advanced several programs to late-stage milestones—reflecting industry-leading capital utilization and execution. The fourth-generation BTK inhibitor and Nav1.8-targeting analgesic both show strong best-in-class potential, while the KRAS-G12D and pan-KRAS programs are well positioned for future breakthroughs. With continued capital support, we are confident Hyperway Pharma will achieve significant clinical and commercial success, ultimately benefiting patients on a global scale.”

About Huagai Capital

Founded in 2012, Huagai Capital is a private equity firm established by seasoned professionals from leading domestic and international investment institutions. Guided by its vision to “become the most trusted capital partner for entrepreneurs and investors,” the firm specializes in healthcare and technology investments, with a strong commitment to cultivating small and medium-sized enterprises into industry leaders. With approximately RMB 30 billion in assets under management, Huagai Capital has successfully supported over 30 portfolio companies in achieving public listings.

About SIP Sungent BioVenture Ventures

SIP Sungent BioVenture Ventures is a leading investment firm focused on early- and growth-stage healthcare opportunities. Headquartered in Suzhou’s bioBAY and operating globally, the firm has invested in over 200 high-potential life sciences companies across four core sectors: new drug development, medical devices, in vitro diagnostics and precision medicine, and healthcare services. With a strong track record of returns, SIP Sungent has supported 20 portfolio companies in achieving public listings on major exchanges, including the Hong Kong Stock Exchange and the STAR Market. The firm has been consistently recognized as one of China’s Top 10 Healthcare Venture Funds and among the country’s Most Active Healthcare Investment Institutions. Backed by a team of seasoned investors and a world-class scientific advisory board, SIP Sungent brings deep expertise in entrepreneurship, venture capital, and biopharmaceutical operations. Leveraging its experience, commitment, and extensive industry network, the firm is dedicated to becoming one of China’s most successful healthcare venture capital platforms.

About Tao Capital

Tao Capital is a leading private equity firm specializing in the healthcare sector. Committed to accelerating the growth of high-potential healthcare enterprises, the firm leverages capital and industry resources to deliver superior medical products and services—ultimately advancing human health. Currently, Tao Capital manages 20 RMB-denominated funds and 4 USD-denominated funds, with a portfolio of 92 outstanding healthcare projects. Among these, 16 have successfully completed IPOs—including one approved by the China Securities Regulatory Commission (CSRC)—such as Bright Eye Hospital Group (301239), Jinxin Fertility Group (HK.1951), Sino Medical Sciences Technology (688108), Innovita (688253), TINAVI (688277), Viva Biotech (HK.1873), Guangzhou LBP Medicine (688393), and Hangzhou AGS MedTech (688581). Looking ahead, more than 10 portfolio companies are expected to enter the IPO process within the next three years.

About Panlin Capital

Panlin Capital is a venture capital firm with deep expertise and influence across the healthcare and technology sectors. Founded in 2010, the firm is guided by the investment philosophy “Technology Creates the Future, Innovation Drives Advancement,” and focuses on identifying high-potential opportunities from angel to Series A stages. Panlin is committed to “finding entrepreneurs among scientists and empowering innovators among entrepreneurs.” In healthcare, Panlin invests in companies developing innovative drugs that address unmet clinical needs in the prevention, diagnosis, and treatment of major diseases, as well as in cutting-edge medical device firms. The firm also actively pursues spin-off opportunities in life sciences and biotechnology. In the technology sector, Panlin targets B2B enterprises focused on enterprise services and data intelligence equipment that drive cost reduction, efficiency gains, and quality improvements. It also supports hard tech companies developing critical, autonomous, and controllable technologies—including advanced equipment and key components.

About Xincheng Fund

Established in 2021, Xincheng Fund is an independently operated venture capital platform initiated by Innovent Biologics Group. It currently manages the InnoPinnacle Fund, jointly founded by Innovent Biologics and Oriza Holdings as general partners, with Innovent Biologics leading fund operations. Xincheng Fund actively supports national innovation strategies and focuses on cutting-edge opportunities in life sciences and healthcare. By leveraging its industrial strengths and strategic advantages, the fund promotes the high-quality development of innovative enterprises. Its investment strategy centers on leading companies in innovative drug development, biotechnology, and related industrial chains, with a strong emphasis on advancing next-generation biopharmaceuticals and breakthrough technologies that address unmet clinical needs.

About Haoyue Capital

Founded in January 2014, Haoyue Capital is a leading industrial investment bank focused on China’s healthcare sector. Headquartered in Shanghai, the firm operates regional offices in Beijing, Shenzhen, Hong Kong, and Singapore. Haoyue Capital combines capital strength with research-driven insights to help high-potential Chinese healthcare enterprises access capital markets and deliver long-term value. The firm closely monitors market dynamics and investment trends across key healthcare segments, including innovative pharmaceuticals, medical devices, in vitro diagnostics (IVD), life sciences, health services, and smart healthcare. As of 2024, Haoyue Capital has completed nearly 400 projects. Over the past decade, it has built deep expertise in private financing, M&A integration, and complex transactions for listed companies—establishing a comprehensive leadership position across the healthcare investment landscape.